First-line therapy for ESBL-producing organisms?

Study for the PANCE Infectious Disease Test. Dive into flashcards and multiple choice questions, each equipped with hints and detailed explanations. Prepare thoroughly for your exam!

Multiple Choice

First-line therapy for ESBL-producing organisms?

Explanation:
Carbapenems are the first-line option for ESBL-producing organisms because ESBLs break down many penicillins and cephalosporins, and many beta-lactamase inhibitor combinations don’t reliably restore activity in these infections. Carbapenems, such as meropenem or ertapenem, resist ESBL hydrolysis and provide reliable bactericidal activity with good tissue penetration, making them effective even with high bacterial loads. Other beta-lactams may seem active in the lab, but clinical failures are more common due to inoculum effects and the presence of additional resistance mechanisms; aztreonam is often unreliable because ESBL producers frequently harbor other enzymes that also degrade it. Therefore, carbapenems remain the standard initial therapy for serious ESBL infections, with stewardship considerations guiding broader use.

Carbapenems are the first-line option for ESBL-producing organisms because ESBLs break down many penicillins and cephalosporins, and many beta-lactamase inhibitor combinations don’t reliably restore activity in these infections. Carbapenems, such as meropenem or ertapenem, resist ESBL hydrolysis and provide reliable bactericidal activity with good tissue penetration, making them effective even with high bacterial loads. Other beta-lactams may seem active in the lab, but clinical failures are more common due to inoculum effects and the presence of additional resistance mechanisms; aztreonam is often unreliable because ESBL producers frequently harbor other enzymes that also degrade it. Therefore, carbapenems remain the standard initial therapy for serious ESBL infections, with stewardship considerations guiding broader use.

More practice questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy